Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Vanda Pharmaceuticals (VNDA) Tops Q4 EPS by 1c
February 10, 2021 4:27 PM ESTVanda Pharmaceuticals (NASDAQ: VNDA) reported Q4 EPS of $0.15, $0.01 better than the analyst estimate of $0.14. Revenue for the quarter came in at $67.65 million versus the consensus estimate of $64 million.
"I am very proud of the significant accomplishments we realized during this challenging year," said Mihael H. Polymeropoulos, M.D.,... More
